Iterum Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ITRM research report →
About the company
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations.
- CEO
- Corey N. Fishman
- IPO
- 2018
- Employees
- 9
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $1.60M
- P/E
- -0.10
- P/S
- 6.83
- P/B
- -0.31
- EV/EBITDA
- -1.44
- Div Yield
- 0.00%
- Gross Margin
- -171.28%
- Op Margin
- -4261.79%
- Net Margin
- -5225.38%
- ROE
- 442.32%
- ROIC
- -63.07%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,774,000 · 35.44%
- EPS
- $-1.26 · 57.43%
- Op Income
- $-18,696,000
- FCF YoY
- 31.95%
- 52W High
- $1.42
- 52W Low
- $0.03
- 50D MA
- $0.21
- 200D MA
- $0.52
- Beta
- 3.01
- Avg Volume
- 16.33M
Get TickerSpark's AI analysis on ITRM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ITRM coverage
Recent articles, reports, and earnings notes.
No research on ITRM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ITRM report →Similar companies
Peers in the same neighborhood.